Your session is about to expire
← Back to Search
ARBs
Multiple Treatments for COVID-19 (CATCO Trial)
Phase 3
Waitlist Available
Led By Srinivas Murthy, MD
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Primary reason for hospitalization or subsequent in-hospital illness is because of acute COVID19 infection
≥ 18 years of age
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights
CATCO Trial Summary
This trial is testing a new way to do clinical trials that is faster and cheaper.
Who is the study for?
Adults hospitalized with acute COVID-19 infection, confirmed by a lab test within the last 14 days. Participants must be at their first hospital admission for COVID-19 and not expected to transfer to a non-participating center or pass away within 24 hours. Exclusions include known allergies to trial drugs, certain pre-existing conditions, pregnancy, breastfeeding, and current use of study drugs.Check my eligibility
What is being tested?
The trial is testing multiple treatments: Artesunate, Imatinib, Infliximab, Dexamethasone (a steroid), and LSALT Peptide in an adaptive design. Patients are randomly assigned to receive one of these interventions alongside standard care for COVID-19.See study design
What are the potential side effects?
Possible side effects may include allergic reactions specific to each drug; liver issues with Imatinib; heart failure risks with Infliximab; immune system suppression from steroids like Dexamethasone; and general medication-related risks such as nausea or rash.
CATCO Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am in the hospital primarily due to COVID-19.
Select...
I am 18 years old or older.
Select...
This is my first hospital visit for COVID-19.
CATCO Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Randomization Dex- Clinical Status
Randomization LSALT- Respiratory support
Randomization WHO- Mortality
Secondary outcome measures
CU admission, hospital and ICU length of stay, days alive and free of vasopressors, ventilation, and renal replacement therapy (RRT
Evaluation of the clinical effectiveness of study drugs
Mortality
+1 moreOther outcome measures
Time to viral clearance of lopinavir/ritonavir as compared to the control arm
CATCO Trial Design
6Treatment groups
Experimental Treatment
Active Control
Group I: LSALT PeptideExperimental Treatment1 Intervention
Subjects will be randomized between LSALT vs standard of care.
Group II: InfliximabExperimental Treatment1 Intervention
Subjects will be randomized Artesunate vs Imatinib vs Infliximab vs standard of care
Group III: ImatinibExperimental Treatment1 Intervention
Subjects will be randomized Artesunate vs Imatinib vs Infliximab vs standard of care
Group IV: DexamethasoneExperimental Treatment1 Intervention
Subjects will be randomized between Dexamethasone vs standard of care.
Group V: ArtesunateExperimental Treatment1 Intervention
Subjects will be randomized Artesunate vs Imatinib vs Infliximab vs standard of care
Group VI: Control (Standard Care)Active Control1 Intervention
This arm will receive standard supportive care guidelines for COVID-19. It is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Artesunate
2005
Completed Phase 4
~3930
Imatinib
2011
Completed Phase 3
~3940
Infliximab
2017
Completed Phase 4
~3280
Dexamethasone
2007
Completed Phase 4
~2590
Find a Location
Who is running the clinical trial?
Sunnybrook Health Sciences CentreLead Sponsor
659 Previous Clinical Trials
1,548,732 Total Patients Enrolled
12 Trials studying COVID-19
7,179 Patients Enrolled for COVID-19
AbbVieIndustry Sponsor
971 Previous Clinical Trials
502,228 Total Patients Enrolled
4 Trials studying COVID-19
1,530 Patients Enrolled for COVID-19
Apotex Inc.Industry Sponsor
8 Previous Clinical Trials
26,120 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am in the hospital primarily due to COVID-19.This is my first hospital visit for COVID-19.I am 18 years old or older.It is expected that the person will not live for more than 24 hours.I do not have severe heart failure, tuberculosis, or allergies to infliximab.I have been on steroids and supplemental oxygen for 10 days.You are allergic to artesunate.Any person can participate in the study without needing to meet any particular requirements for selection.You have tested positive for COVID-19 within 14 days before the study starts.I am currently taking a medication that is part of this study.I may be excluded from some drugs but can still participate in other parts of the study.I am taking steroids for a reason other than COVID-19.You tested positive for COVID-19 within 14 days before the study starts.You are pregnant, breastfeeding, or have a severe allergy to imatinib. Additionally, your liver enzymes are more than 5 times the normal limit for imatinib.
Research Study Groups:
This trial has the following groups:- Group 1: Artesunate
- Group 2: Imatinib
- Group 3: Infliximab
- Group 4: Dexamethasone
- Group 5: LSALT Peptide
- Group 6: Control (Standard Care)
Awards:
This trial has 2 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger